Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBFT02 in Frontotemporal Dementia with GRN or C9ORF72 Mutations
NCT04747431Phase 2Terminated
- Sponsor
- Passage Bio
- Start
- Sep 2021
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 5
01
Overview
Phase 2, open-label trial of PBFT02 in frontotemporal dementia (FTD) (2 cohorts), sponsored by Passage Bio. Primary endpoints: Number of Participants with Treatment-Related Adverse Events and Serious Adverse Events at 5 years, Change in Nerve Conduction Velocity and Amplitude from Baseline on Nerve Conduction Studies at 5 years and 1 more. Started Sep 2021; status: terminated.
02
Drugs
PBFT02
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04747431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747431.